<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100770">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01840059</url>
  </required_header>
  <id_info>
    <org_study_id>2012HS001B</org_study_id>
    <nct_id>NCT01840059</nct_id>
  </id_info>
  <brief_title>Renal Denervation in Heart Failure With Preserved Ejection Fraction</brief_title>
  <acronym>RDT-PEF</acronym>
  <official_title>A Randomised Controlled Trial Investigating the Effect of Transcatheter Renal Sympathetic Denervation on Symptoms and Cardiac Function in Patients With Heart Failure With Preserved Ejection Fraction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Brompton &amp; Harefield NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal Brompton &amp; Harefield NHS Foundation Trust</source>
  <oversight_info>
    <authority>United Kingdom: National Health Service</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether renal sympathetic denervation (RSD)(a
      treatment that lowers the activity of the sympathetic nervous system) is useful in the
      management of patients with heart failure with preserved ejection fraction (HF-PEF).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Increasing evidence suggests an important role of activation of the sympathetic nervous
      system (SNS) in heart failure with preserved left ventricular ejection fraction. The current
      study aims to evaluate efficacy  of renal sympathetic denervation for the modulation of the
      SNS in patients with HF-PEF.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Symptoms</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Minnesota Living with Heart Failure Questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Exercise Function</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Peak VO2 (Oxygen Uptake) on cardiopulmonary exercise testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Heart Failure Biomarker</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>BNP (Natriuretic peptide)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in LV (Left Ventricle) filling pressure</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>E/E' on echocardiography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in LV remodelling</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>LV mass index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Left atrial (LA) size</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>LA volume index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Autonomic function</measure>
    <time_frame>3 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Heart rate variability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Renal function</measure>
    <time_frame>3 and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Urea and Creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Vascular function</measure>
    <time_frame>3 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Aorta MRI (Magnetic Resonance Imaging)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Autonomic function</measure>
    <time_frame>3 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>mIBG radiotracer assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in neurohormones</measure>
    <time_frame>3 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Neurohormones</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in renal blood flow</measure>
    <time_frame>3 and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Renal MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood pressure</measure>
    <time_frame>3 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>ABPM (Ambulatory Blood Pressure Monitoring)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Endothelial function</measure>
    <time_frame>3 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>EndoPat</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cardiac Failure</condition>
  <arm_group>
    <arm_group_label>Renal sympathetic denervation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal denervation using the Medtronic Symplicity catheter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>HF-PEF patients who will serve as control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Renal sympathetic denervation</intervention_name>
    <description>A fit for purpose radiofrequency catheter is guided to the renal artery using fluoroscopy. This is connected to an external RF generator. RF energy is applied through the catheter to the renal artery wall with the goal of disrupting the sympathetic nerves which run in the adventitia</description>
    <arm_group_label>Renal sympathetic denervation</arm_group_label>
    <other_name>Medtronic Symplicity Catheter</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of HF-PEF using ESC 2012 guidelines

          -  EF&gt;50%

          -  NHYA 2-3

        Exclusion Criteria:

          -  Previously documented EF&lt;40%

          -  Hypertrophic, restrictive, dilated cardiomyopathy

          -  Significant valvular heart disease

          -  Unfavourable renal artery anatomy for renal denervation

          -  eGFR&lt;45

          -  Contraindication to MRI

          -  Myocardial infarction, unstable angina or cerebrovascular accident in last 6 months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlo di Mario</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Brompton Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hitesh Patel</last_name>
    <email>h.patel3@rbht.nhs.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hitesh Patel</last_name>
      <email>h.patel3@rbht.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Carlo di Mario</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Sobotka PA, Krum H, BÃ¶hm M, Francis DP, Schlaich MP. The role of renal denervation in the treatment of heart failure. Curr Cardiol Rep. 2012 Jun;14(3):285-92.</citation>
    <PMID>22392370</PMID>
  </reference>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 22, 2013</lastchanged_date>
  <firstreceived_date>April 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiac Failure</keyword>
  <keyword>Autonomic Denervation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
